Dr. Rudin on the Design of the KEYNOTE-604 Trial in ES-SCLC

Video

Charles M. Rudin, MD, PhD, discusses the design of the phase 3 KEYNOTE-604 trial in extensive-stage small cell lung cancer.

Charles M. Rudin, MD, PhD, medical oncologist, chief, Thoracic Oncology Service, co-director, Druckenmiller Center for Lung Cancer Research, Sylvia Hassenfeld Chair in Lung Cancer Research, Memorial Sloan Kettering Cancer Center, discusses the design of the phase 3 KEYNOTE-604 trial in extensive-stage small cell lung cancer (ES-SCLC).

In June 2019, the FDA approved pembrolizumab for the treatment of patients with metastatic SCLC who experience disease progression on or after platinum-based chemotherapy and at least 1 prior line of therapy.

KEYNOTE-604 evaluated whether pembrolizumab plus etoposide and platinum induced an improved response compared with placebo as first-line treatment for patients with ES-SCLC, says Rudin.

Findings from the study showed that the PD-1 inhibitor plus chemotherapy significantly improved progression-free survival compared with placebo.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD